Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2015	Jul. 30, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		59,006,817

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,268	$ 774
Marketable securities (Note 6)	9,651	11,322
Accounts receivable, net of allowances of $7 and $5	109	76
Accrued investment income	53	66
Inventories, net (Note 7)	217	304
Prepaid expenses and other current assets	623	471
Other current deferred assets	3	218
Total current assets	11,924	13,231
Property, plant and equipment, net	1,121	957
Intangible asset, net of accumulated amortization of $258 and $155 (Note 3)	1,742	1,845
Other assets	175	0
Total assets	14,962	16,033
Current liabilities:
Accounts payable	261	217
Accrued expenses (Note 8)	863	568
Other current liabilities	49	26
Accrued interest	65	70
Sales returns liability	195	0
Deferred revenue	0	353
Current maturities of long-term debt (Note 9)	2,419	1,758
Total current liabilities	3,852	2,992
Long-term debt, net of discount of $251 and $281, and debt issuance costs of $128 and $162 (Note 9)	6,629	7,799
Long-term portion of accrued interest	291	190
Total liabilities	10,772	10,981
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 49,217 and 48,848 shares issued and outstanding at 2015 and 2014, respectively	492	488
Additional paid-in capital	367,456	366,898
Accumulated deficit	(363,745)	(362,321)
Accumulated other comprehensive loss	(13)	(13)
Total stockholders' equity	4,190	5,052
Total liabilities and stockholders' equity	$ 14,962	$ 16,033

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Accounts receivable, net of allowances	$ 7	$ 5
Finite-lived intangible assets accumulated amortization	258	155
Long-term debt, net of debt discount	251	281
Debt Instrument Issuance Cost	$ 128	$ 162
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	49,217	48,848
Common stock, shares outstanding	49,217	48,848

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Royalty revenue	$ 0	$ 1	$ 0	$ 4
Product sales, net	91	34	448	73
License fee revenue	250	0	5,250	0
Total revenues, net	341	35	5,698	77
Operating expenses:
Cost of sales (excluding inventory write-down)	98	42	422	80
Inventory write-down (Note 7)	47	68	307	201
Research and development	511	1,281	1,475	2,719
Selling, marketing, general and administrative	2,083	1,916	4,380	4,175
Total operating expenses	2,739	3,307	6,584	7,175
Operating loss	(2,398)	(3,272)	(886)	(7,098)
Non-Operating income (expense):
Investment income	36	53	71	97
Interest expense (Note 9)	(301)	(302)	(609)	(603)
Other expense	0	0	0	(5)
Total other expense, net	(265)	(249)	(538)	(511)
Loss before income taxes	(2,663)	(3,521)	(1,424)	(7,609)
Provision for income taxes	0	0	0	0
Net loss	(2,663)	(3,521)	(1,424)	(7,609)
Other comprehensive (loss) income:
Unrealized (losses) gains on securities	(31)	21	0	50
Total other comprehensive (loss) income	(31)	21	0	50
Comprehensive loss	$ (2,694)	$ (3,500)	$ (1,424)	$ (7,559)
Loss per share:
Basic	$ (0.05)	$ (0.07)	$ (0.03)	$ (0.16)
Diluted	$ (0.05)	$ (0.07)	$ (0.03)	$ (0.16)
Weighted average shares outstanding:
Basic	49,233	48,848	49,101	48,846
Diluted	49,233	48,848	49,101	48,846

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2014	$ 5,052	$ 488	$ 366,898	$ (362,321)	$ (13)
Beginning Balance (in shares) at Dec. 31, 2014		48,848
Net loss	(1,424)	0	0	(1,424)	0
Other comprehensive income (loss)	0	0	0	0	0
Share-based compensation	311	0	311	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		99
Net distribution of common stock pursuant to restricted stock unit award plan	1	1	0	0	0
Modification to warrants issued with promissory notes	33	0	33	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8 (in shares)		270
Issuance of common stock under “at the market” offerings, net of offering costs of $8	217	3	214	0	0
Ending Balance at Jun. 30, 2015	$ 4,190	$ 492	$ 367,456	$ (363,745)	$ (13)
Ending Balance (in shares) at Jun. 30, 2015		49,217

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows from Operating Activities:
Net loss	$ (1,424)	$ (7,609)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	59	58
Provision to reduce inventory to net realizable value	307	201
Provision for sales returns	195	0
Share-based compensation	311	455
Amortization of debt discount and debt issue costs	97	93
Amortization of bond premium in marketable securities	76	138
Amortization of intangible asset	103	0
Loss on sales of marketable securities	0	5
Loss on disposal of property and equipment	20	1
Changes in assets and liabilities:
Accounts receivable	(33)	108
Accrued investment income	13	18
Inventories	(220)	(394)
Prepaid expenses and other current assets	(152)	83
Other current deferred assets	215	(7)
Other assets	(175)	3
Accounts payable	44	(160)
Accrued expenses	295	902
Deferred revenue	(353)	20
Accrued interest - current and long term	96	0
Other current liabilities	23	32
Net cash used in operating activities	(503)	(6,053)
Cash Flows from Investing Activities:
Purchases of marketable securities	0	(1,540)
Proceeds from sale and maturities of marketable securities	1,595	1,361
Acquisition of product rights	0	(2,000)
Additions to property, plant and equipment	(257)	(47)
Proceeds from disposal of property and equipment	14	0
Net cash provided by (used in) investing activities	1,352	(2,226)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	8
Proceeds from distribution of restricted stock units	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	0	(529)
Proceeds from "at-the-market" offering	225	0
Offering transaction costs	(8)	0
Principal payments on debt	(573)	0
Net cash used in financing activities	(355)	(520)
Net increase (decrease) in cash and cash equivalents	494	(8,799)
Cash and cash equivalents at beginning of year	774	12,340
Cash and cash equivalents at end of period	1,268	3,541
Cash paid during the year for:
Interest	414	348
Income taxes	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Outstanding	298,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.504
Additions To Debt Instrument Unamortized Discount	$ 33
Maximum [Member]
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.595
Minimum [Member]
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.504
Stock options
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		24,000
Common stock withheld in exercise costs in shares		16,000
Common stock withheld in exercise costs		32
Withholding of exercise cost in shares		2,000
Minimum statutory withholding payroll taxes withheld		4
Common Stock issued upon exercise		6,000
Restricted Stock Unit
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		829,000
Common stock withheld in exercise costs in shares		4,000
Common stock withheld in exercise costs		7
Withholding of exercise cost in shares		315,000
Minimum statutory withholding payroll taxes withheld		$ 525
Common Stock issued upon exercise		510,000

DESCRIPTION OF BUSINESS

6 Months Ended

Jun. 30, 2015

Description Of Business Disclosure [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Oxaydo™ Tablets (formerly known as Oxecta®) (oxycodone HCl, CII), is the first approved product utilizing Aversion® in the United States. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. We are advised that Egalet plans to launch Oxaydo in the United States in the third quarter of 2015. We have also developed Impede® Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. We launched our first Impede Technology product, Nexafed®, into the United States market in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC (“Bayer”) entered into a License and Development Agreement to provide Bayer with an exclusive worldwide license to our Impede Technology for an undisclosed methamphetamine resistant pseudoephedrine – containing product, and providing for our joint development of such product utilizing our Impede™ Technology for the U.S. market. Our third technology, Limitx, is designed to retard the release of active drug ingredients when an excess number of tablets are accidently or purposefully ingested. In August 2014, we were awarded a grant from the National Institute on Drug Abuse to advance early stage development of our Limitx technology.

ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Jun. 30, 2015

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

ACCOUNTING PRONOUNCEMENTS

NOTE 2 – ACCOUNTING PRONOUNCEMENTS

Revenue from Contracts with Customers

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018.

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, which will explicitly require management to assess an entity’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Currently, there is no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for the first annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of adopting this update on its financial statements.

Presentation of Debt Issue Costs

In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. Early adoption of the amendments is permitted and the Company elected to adopt this guidance effective April 1, 2015. The Company adopted the guidance to implement the simplified presentation prescribed as the purpose of the amendment. The new guidance has been applied on a retrospective basis, wherein the consolidated balance sheets of December 31, 2014 have been retrospectively adjusted to reflect the effects of applying the new guidance. As a result of the change to the December 31, 2014 consolidated balance sheet, deferred debt issuance costs and long-term debt decreased and increased, respectively, by $162. After the retrospective application to December 31, 2014, subsequent amortization of the deferred debt issuance costs results in an increase to long-term debt.

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

6 Months Ended

Jun. 30, 2015

Research and Development Disclosure [Abstract]

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT

NOTE 3 - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

Pfizer Agreement

In October 2007, we entered into a License, Development and Commercialization Agreement, or the Pfizer Agreement, with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer, to develop and commercialize in the United States, Canada and Mexico certain opioid analgesic products utilizing our Aversion Technology. Aversion Oxycodone was approved by the U.S. Food and Drug Administration, or FDA, on June 17, 2011 and sales of Aversion Oxycodone, under Pfizer’s brand name Oxecta, commenced in February 2012. For sales of Aversion Oxycodone occurring on and following February 2, 2013 (the one year anniversary of first commercial sale), Pfizer paid us a royalty of 5% of net sales of Aversion Oxycodone.

On September 24, 2012, we entered into a letter agreement with Pfizer which provided for the termination of Pfizer’s license to our Aversion Technology used in three development-stage products licensed to Pfizer and for the return of these products to us. On April 9, 2014, we entered into a second letter agreement with Pfizer providing for the termination of the Pfizer Agreement and the return of Aversion Oxycodone to us effective April 9, 2014 in exchange for a one-time termination payment of $2.0 million. Pfizer’s royalty payment obligations relating to Aversion Oxycodone ceased effective April 9, 2014 and all royalty payments due to us have been received. Our termination payment of $2.0 million has been recorded on our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent for Aversion Oxycodone. The recorded value of the intangible asset will be periodically assessed for impairment. We also purchased from Pfizer selected raw and packaging material inventories for $260 thousand relating to the Aversion Oxycodone product. During the quarter ended March 31, 2015, we recorded a 100% reserve against these inventories which is reflected in operating expense.

Egalet Agreement

On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we are transferring the approved NDA for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and will pay us a $2.5 million milestone on the earlier to occur of (A) the launch of Oxaydo and (B) January 1, 2016. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We will receive from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). In any calendar year in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo. Royalties will be reduced upon the entry of generic equivalents, as well for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Egalet also may terminate the Agreement prior to the launch of Oxaydo on 30 days prior written notice upon the occurrence of serious safety issues, regulatory restrictions and intellectual property issues, in each case involving Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

Paragraph IV ANDA Litigation and License Grants

On or about September 17, 2012, the FDA began accepting ANDAs referencing Oxaydo. To date, we have received Paragraph IV Certification Notices under 21 U.S.C. 355(j) (a Paragraph IV Notice) from five separate generic sponsors of an ANDA for a generic drug listing Oxaydo as the reference listed drug. The Paragraph IV Notices state that each generic sponsor believes that our Aversion Technology patents listed in FDA’s Orange Book are invalid, unenforceable or not infringed. We initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc., and Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book.

We dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry.

We have entered into distinct Settlement Agreements with each of Par, Impax, Ranbaxy and Sandoz to settle our patent infringement actions. Par is the first filer of an ANDA for a generic Oxaydo product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations. Par is entitled to launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025. In certain limited circumstances, our license to Par would become effective prior to January 1, 2022. Par is required to pay us royalties in the range of 10% to 15% of Par’s net profits from the sale of its generic Oxaydo product.

Impax and Sandoz, are entitled to launch their generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxaydo® product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxaydo® product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax and Sandoz would become effective prior to such time. In certain circumstances, Sandoz may be required to pay us a royalty on net profits of their generic Oxaydo product.

We have entered into a Settlement Agreement with Ranbaxy Inc. to settle our patent infringement action pending in the United States District Court for the District of Delaware. The Settlement Agreement with Ranbaxy provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product.

Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

Bayer Agreement

On June 15, 2015, we and Bayer entered into a License and Development Agreement granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine –containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Agreement also grants Bayer first right to negotiate a license to the Impede technology for certain other products.

We and Bayer will form a joint development committee to coordinate development of the Bayer Licensed Product. We will be eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed product in countries with patent coverage and a reduced royalty elsewhere.

The term of the Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Agreement in its entirety if the other party materially breaches the Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time.

Purdue Pharma

The Company received a $250 thousand payment from Purdue Pharma L.P. in June 2015 relating to a December 2014 agreement to settle a patent interference action on U.S. Patent No. 8,101,630 issued to Acura.

REVENUE RECOGNITION

6 Months Ended

Jun. 30, 2015

Revenue Recognition [Abstract]

REVENUE RECOGNITION

NOTE 4 - REVENUE RECOGNITION

Revenue is generally realized or realizable and earned when there is persuasive evidence an arrangement exists, delivery has occurred or services rendered, the price is fixed and determinable, and collection is reasonably assured. We record revenue from our Nexafed product sales when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated.

Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return for a period of up to twelve months after the product expiration. The Nexafed products currently have a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers and accordingly we had deferred revenue. During the first quarter ended March 31, 2015 we determined we had obtained sufficient sales returns history to reasonably estimate future returns. As a result of this change, we recorded a one-time adjustment in the first quarter ended March 31, 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $314 thousand after recording an allowance for sales returns of $120 thousand, and cost of sales of $255 thousand. At June 30, 2015, we have a $195 thousand sales returns liability which will be reviewed against sales returns activity each quarter. Revenue is being recognized at the time the products are sold to a customer.

Commencing in February 2013, we began earning royalties based on net sales of Aversion Oxycodone by Pfizer. We earned royalties of approximately $4 thousand for the six months ended June 30, 2014. The Pfizer Agreement was terminated effective April 9, 2014 and Pfizer’s royalty payment obligations ceased as of such date. All royalties owed to us have been received.

Shipping and Handling Costs

We record our shipping and handling costs in selling expenses. The amounts recorded to selling expenses from the shipments of Nexafed products during each of the six month periods ended June 30, 2015 and 2014 were not material.

RESEARCH AND DEVELOPMENT ACTIVITIES

6 Months Ended

Jun. 30, 2015

Research and Development [Abstract]

RESEARCH AND DEVELOPMENT ACTIVITIES

NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES

Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. We did not have any accrued CRO costs and clinical trial study expenses at either June 30, 2015 or December 31, 2014. We did not have any prepaid CRO costs and clinical trial study expenses at either June 30, 2015 or December 31, 2014.

INVESTMENTS IN MARKETABLE SECURITIES

6 Months Ended

Jun. 30, 2015

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS IN MARKETABLE SECURITIES

NOTE 6 - INVESTMENTS IN MARKETABLE SECURITIES

Investments in marketable securities consisted of the following (in millions):

	June 30,		December 31,
	2015		2014
Marketable securities:
Corporate bonds - maturing within 1 year	$	3.0	$	3.5
Corporate bonds - maturing after 1 year and through March 2017		1.7		2.8
Exchange-traded funds		5.0		5.0
Total marketable securities	$	9.7	$	11.3

The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our investments are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs.

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	June 30, 2015
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	4.7	$	-	$	-	$	4.7
Exchange-traded funds		5.0		-		-		5.0
Total – Current	$	9.7	$	-	$	-	$	9.7

	December 31, 2014
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Our assets measured at fair value or disclosed at fair value on a recurring basis as at June 30, 2015 and December 31, 2014 consisted of the following (in millions):

	June 30, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	4.7	$	-	$	4.7	$	-
Exchange-traded funds		5.0		5.0		-		-
Total	$	9.7	$	5.0	$	4.7	$	-

	December 31, 2014
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	6.3	$	-	$	6.3	$	-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3		5.0		6.3		-

Accumulated Other Comprehensive Income (Loss)

Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at June 30, 2015 and December 31, 2014 consisted of unrealized losses on securities of $13 thousand.

INVENTORIES

6 Months Ended

Jun. 30, 2015

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 7 – INVENTORIES

Inventories consist of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed products. During 2014, we purchased raw and packaging material inventories for $260 thousand from Pfizer on the Oxaydo product we reacquired from them. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. During the quarter ended March 31, 2015, we recorded a $260 thousand reserve against the raw and packaging material inventory on our Oxaydo product as Egalet will secure its own material requirements. During the quarter ended June 30, 2015, we applied the reserve against our packaging material inventory and we recorded a $47 thousand reserve against finished good inventory. We recorded finished good inventory reserves of $133 thousand and $68 thousand during each of the first and second quarters of 2014, respectively.

We had recorded Nexafed deferred revenue of $0.35 million at December 31, 2014. The related cost of sales of $0.22 million at December 31, 2014 is reported in our balance sheet in the other current deferred assets account and excluded from the reported year end inventories. We recognize both the revenue and cost of sales on these Nexafed shipments once the right of return no longer exists or adequate history and information becomes available to estimate sales returns. During the first quarter ended March 31, 2015, we determined we had obtained sufficient sales returns history to reasonably estimate future returns. As a result of this change, we recorded a one-time adjustment in the first quarter ended March 31, 2015 to recognize revenue that had previously been deferred, resulting in additional net revenue of $314 thousand and cost of sales of $255 thousand. Revenue is being recognized at the time the products are sold to a customer.

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories are summarized as follows (in thousands):

	June 30,		December 31,
	2015		2014
Raw and packaging materials	$	126	$	260
Finished goods		264		44
Total		390		304
Less: reserve for raw materials		(126)		(-)
Less: reserve for finished goods		(47)		(-)
Net	$	217	$	304

DEBT

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

DEBT

NOTE 9 – DEBT

On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The full principal amount of the Term Loan was funded on December 27, 2013. We are using the proceeds of the Loan Agreement for general working capital and to fund our business requirements. The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest–only payments until the April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As of June 30, 2015 we have made $768 thousand in principal payments. As security for its obligations under the Loan Agreement, the Company granted Lender a security interest in substantially all of its existing and after–acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 298 thousand shares of our common stock at an exercise price equal to $1.595 per share (the “Warrants”). We recorded $400 thousand as debt discount associated with the fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the Warrants was lowered from $1.595 to $0.504 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment) and we recorded additional debt discount of $33 representing the fair value of the warrant modification, (ii) we agreed to maintain a $2.5 million cash reserve until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.

The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 2% of the principal prepaid, if prepaid prior to December 27, 2015, and 1% of the principal prepaid if prepaid after December 27, 2015. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We will incur and accrue additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of 10.16%.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non–payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt at June 30, 2015 is summarized below (in thousands):

Debt	Current		Long-term		Total
Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
Principal payments		(573)		-		(573)
Classification		1,234		(1,234)		-
Balance at Jun 30, 2015	$	2,419	$	7,008	$	9,427

Debt Discount	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(281)	$	(281)
Modification of warrants		-		(33)		(33)
Amortization expense		-		63		63
Balance at Jun 30, 2015	$	-	$	(251)	$	(251)

Debt Issuance Costs	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(162)	$	(162)
Additions		-		-		-
Amortization expense		-		34		34
Balance at Jun 30, 2015	$	-	$	(128)	$	(128)

Net Debt at Jun 30, 2015	$	2,419	$	6,629	$	9,048

Our interest expense during the three and six months ended June 30, 2015 and 2014 consisted of the following (in thousands):

	Three months Ended June 30,				Six months Ended June 30,
	2015		2014		2015		2014
Interest expense:
Term loan	$	251	$	255	$	512	$	510
Debt discount		33		30		63		59
Debt issue costs		17		17		34		34
Total interest expense	$	301	$	302	$	609	$	603

The remaining annual principal payments on the debt as of June 30, 2015 is as follows (in thousands):

Principal Payments
2015	$	1,185
2016		2,522
2017		2,741
2018		2,979
Total	$	9,427

EQUITY FINANCING

6 Months Ended

Jun. 30, 2015

Equity [Abstract]

EQUITY FINANCING

NOTE 10 – EQUITY FINANCING

Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we may sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $13 million. We did not sell any shares of our common stock pursuant to our prospectus supplement during the year ended December 31, 2014. During the three and six months ended June 30, 2015, we sold approximately 270 thousand shares of our common stock for gross proceeds of approximately $0.23 million. Transaction costs were approximately $8 thousand. The net proceeds of approximately $0.22 million will be used for general corporate purposes, which may include working capital, capital expenditures, research, development and marketing expenditures, clinical trial expenditures, acquisitions of new technologies, and possible investments in or acquisitions of, complementary businesses or technologies. In order to allow for the sale of our shares of common stock under our shelf registration statement pursuant to the Placement Agency Agreement and Securities Purchase Agreement described below, on June 30, 2015, we and MLV & Co., LLC, as sales agent, terminated the At Market Issuance Sales Agreement dated April 18, 2013, thereby terminating any further “at the market offerings” under our prospectus supplement filed with the SEC on April 18, 2013.

On June 30, 2015, we entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), pursuant to which we engaged Roth to act as sole placement agent in a registered direct offering (the “Offering”) of 9.79 million shares of our common stock, par value $.01. On June 30, 2015, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which we agreed to sell 9.79 million shares of our common stock at a price of $0.78 per share to the Purchasers in the Offering, for gross proceeds to the Company of approximately $7.63 million, before expenses. The Offering was made pursuant to a prospectus supplement dated June 30, 2015 filed with the Securities and Exchange Commission in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-187075), which became effective on March 15, 2013, and the related base prospectus included in the Registration Statement, as supplemented by the prospectus supplement. The transactions contemplated by the Placement Agency Agreement and the Purchase Agreement closed on July 7, 2015.

Pursuant to the terms of the Placement Agency Agreement, we paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering and reimbursed Roth $35 thousand for its expenses. We estimate that net proceeds from the Offering, after these and other legal expenses, will be approximately $7.0 million.

COMMON STOCK WARRANTS

6 Months Ended

Jun. 30, 2015

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

NOTE 11 - COMMON STOCK WARRANTS

We have outstanding common stock purchase warrants (“warrants”) exercisable for 298 thousand shares of our common stock having an exercise price of $0.504 per share with an expiration date in December 2020. See Note 9 for a discussion of the reduction of the exercise price of the warrants to $0.504 per share. These warrants contain a cashless exercise feature. Our common stock warrant activity during the six months ended June 30, 2015 and 2014 is shown below:

	Six months Ended June 30,
	2015				2014
	Number (000’s)		Weighted Average Exercise Price		Number (000’s)		Weighted Average Exercise Price
Outstanding, beginning		298	$	1.60		2,154	$	3.15
Issued		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding, ending		298	$	0.50		2,154	$	3.15

SHARE-BASED COMPENSATION

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE-BASED COMPENSATION

NOTE 12 - SHARE-BASED COMPENSATION

Share-based Compensation

We have three share-based compensation plans covering stock options and RSUs for our employees and directors.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the fair-value method. The fair value of the RSUs is the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations comprised the following (in thousands):

	Three months Ended June 30,				Six months Ended June 30,
	2015		2014		2015		2014
Research and development expense:
Stock options	$	39	$	56	$	78	$	113

General and administrative expense:
Stock options	$	88	$	141	$	186	$	282
Restricted stock units		24		60		47		60
Subtotal	$	112	$	201	$	233	$	342

Total	$	151	$	257	$	311	$	455

Stock Option Award Plans

We have one stock option plan in effect, and one stock option plan has expired by its terms, but pursuant to which stock options have been granted and remain outstanding. Our stock option award activity during the six months ended June 30, 2015 and 2014 is shown below:

	Six months Ended June 30,
	2015				2014
	Number of Options (000’s)		Weighted Average Exercise Price		Number of Options (000’s)		Weighted Average Exercise Price
Outstanding, beginning		4,556	$	4.14		3,738	$	4.99
Granted		-		-		-		-
Exercised		-		-		(31)		1.30
Forfeited or expired		(75)		5.25		-		-
Outstanding, ending		4,481	$	4.13		3,707	$	5.02
Options exercisable		3,719	$	4.82		3,295	$	5.42

No stock options were exercised during the six months ended June 30, 2015. During the six months ended June 30, 2014, a total of 31 thousand stock options were exercised by our employees. Of the total amount of these stock option exercises, 24 thousand of stock options were exercised under various cashless exercise features of the plan. Our employees elected to have 18 thousand shares withheld in satisfaction of $36 thousand for both the exercise costs and withholding tax obligations on those options, resulting in the net issuance of 13 thousand shares of common stock from all stock option exercises.

Restricted Stock Unit Award Plans

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.

A summary of the grants under the RSU Plans consisted of the following (in thousands):

	Six months Ended June 30,
		2015		2014
		Number of RSUs	Number of Vested RSUs	Number of RSUs	Number of Vested RSUs
Outstanding, beginning		147	147	829	829
Granted		206	-	147	-
Distributed		(129)	(129)	(829)	(829)
Vested		-	103	-	74
Forfeited or expired		-	-	-	-
Outstanding, ending		224	121	147	74

2005 Restricted Stock Unit Award Plan

Under our 2005 RSU Plan, one-fourth of vested shares of common stock underlying RSU awards of 3.3 million shares will be distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014. On January 1, 2014, 0.50 million shares were distributed to the holders while 0.33 million shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $0.5 million withholding tax obligations.

All RSUs granted under the 2005 RSU Plan had been distributed effective January 1, 2014.

2014 Restricted Stock Unit Award Plan

Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 2.0 million shares of our common stock pursuant to awards under the 2014 RSU Plan. As of June 30, 2015, 1.65 million shares are available for award under the 2014 RSU Plan.

Information about the awards under the 2014 RSU Plan is as follows:

⋅

On May 1, 2014, we awarded approximately 37 thousand RSUs to each of our 4 non-employee directors. Such RSU awards vested 50% on June 30, 2014 and 25% on each of September 30 and December 31, 2014. Such non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet. The liability was $26 thousand at December 31, 2014. Accordingly the vested portion of the awards containing the cash settlement feature are being marked-to-market each reporting period until they are distributed. Marked-to-market accounting can create fluctuations in our compensation expense including the need to record additional expense. RSU awards are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

⋅

On January 2, 2015, we awarded approximately 51.5 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting and the liability recorded in the Company’s balance sheet was $49 thousand at June 30, 2015. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards will be distributed on January 4, 2016.

Information about the distribution of shares under the 2014 RSU Plan is as follows:

⋅

On January 2, 2015, 129 thousand RSUs from the May 1, 2014 award were distributed and 18 thousand RSUs were deferred until a future distribution date. Of the 129 thousand RSUs distributed, 99 thousand RSUs were distributed in common stock and 30 thousand RSUs were settled in cash.

INCOME TAXES

6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 13 – INCOME TAXES

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both June 30, 2015 and December 31, 2014, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss (“NOL”) carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. We have approximately $51.5 million federal income tax benefits at December 31, 2014 derived from $151.4 million Federal NOLs at the U.S. statutory tax rate of 34% and $2.9 million state NOLs, available to offset future taxable income, some of which have limitations for use as prescribed under IRC Section 382. Our Federal and state NOLs will expire in varying amounts between 2016 and 2034 if not used, and those expirations will cause fluctuations in our valuation allowances. As of December 31, 2014 we had federal research and development tax credits of approximately $1.1 million, which expire in the years 2024 through 2034. We also had approximately $0.3 million of Indiana state research and development tax credits, which expire in the years 2015 through 2017.

EARNINGS PER SHARE ("EPS")

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

EARNINGS PER SHARE ("EPS")

NOTE 14 – EARNINGS PER SHARE (“EPS”)

Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 12). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2015 and 2014 as the Company reported a net loss for the three and six month periods, and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Three months Ended June 30,				Six months Ended June 30,
	2015		2014		2015		2014
EPS – basic and diluted
Numerator: net loss	$	(2,663)	$	(3,521)	$	(1,424)	$	(7,609)
Denominator:
Common shares		49,163		48,848		49,055		48,846
Vested RSUs		70		-		46		-
Basic and diluted weighted average shares outstanding		49,233		48,848		49,101		48,846
EPS – basic and diluted	$	(0.05)	$	(0.07)	$	(0.03)	$	(0.16)

Excluded securities:
Common shares issuable:
Stock options		4,481		3,707		4,481		3,707
Nonvested RSUs		103		73		103		73
Common stock warrants		298		2,154		298		2,154
Total excluded common shares		4,882		5,934		4,882		5,934

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 15 – COMMITMENTS AND CONTINGENCIES

Purdue Pharma Complaint

In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. patent 8,389,007. The complaint seeks injunctive relief as well as awards of damages and attorneys’ fees. We deny the allegations in the complaint, believe they are without merit and are defending the action vigorously.

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

In the Pennsylvania action, over 200 lawsuits have been filed against Acura and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 89 pending cases against us, with more than 445 individual plaintiffs.

In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by Acura. We discontinued manufacture and distribution of generic metoclopramide more than 18 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases.

In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. In June 2012, the New Jersey trial court dismissed all of the New Jersey cases pending against Acura with prejudice. It is possible that this ruling may eventually be appealed by plaintiffs at the conclusion of the litigation in the trial court.

In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing decision.

In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al., No. 14-711 (U.S.) seeking reversal of the Pennsylvania state court decision. On April 27, 2015, the U.S. Supreme Court denied this Petition and this matter has been returned to the trial court for further proceedings. Pending a further court order, these proceedings are stayed. On July 16, 2015, the court has scheduled a conference to address lifting the stay and to confirm procedures for further litigation. To the extent, however, that plaintiffs intend to pursue these claims, Acura nonetheless remains optimistic that most, if not all, of these Philadelphia cases will eventually be dismissed against it based upon the favorable aspects of the Superior Court’s narrow preemption ruling and lack of product identification, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by Acura’s insurance carrier.

In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett decision. Thus far, Acura and most Generic Defendants have not been required to file answers or other responsive pleadings in each individual case in which they are named defendants. However, the individual cases against Acura have been stayed pending further action by the trial court. Subject to further developments, plaintiffs may be permitted to proceed with these lawsuits against Acura including state law claims based on (1) failing to communicate warnings to physicians through “Dear Doctor” letters; and (2) failure to update labeling to adopt brand labeling changes. The California trial court also has acknowledged the preemptive effect of Mensing so that any claim “that would render the generic defendants in violation of federal law if they are found responsible under a state law cause of action, would not be permissible.” To date, however, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by Acura. Therefore, we expect the number of plaintiffs with possible claims to be reduced voluntarily or by motion practice. Action will be taken in an effort to dismiss Acura from these cases, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.

As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of June 30, 2015 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.

Facility Lease

The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2016 for approximately $25 thousand annually.

INVESTMENTS IN MARKETABLE SECURITIES (Tables)

6 Months Ended

Jun. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Marketable securities

Investments in marketable securities consisted of the following (in millions):

	June 30,		December 31,
	2015		2014
Marketable securities:
Corporate bonds - maturing within 1 year	$	3.0	$	3.5
Corporate bonds - maturing after 1 year and through March 2017		1.7		2.8
Exchange-traded funds		5.0		5.0
Total marketable securities	$	9.7	$	11.3

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	June 30, 2015
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	4.7	$	-	$	-	$	4.7
Exchange-traded funds		5.0		-		-		5.0
Total – Current	$	9.7	$	-	$	-	$	9.7

	December 31, 2014
	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

Fair Value, Assets Measured on Recurring Basis

Our assets measured at fair value or disclosed at fair value on a recurring basis as at June 30, 2015 and December 31, 2014 consisted of the following (in millions):

	June 30, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	4.7	$	-	$	4.7	$	-
Exchange-traded funds		5.0		5.0		-		-
Total	$	9.7	$	5.0	$	4.7	$	-

	December 31, 2014
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	6.3	$	-	$	6.3	$	-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3		5.0		6.3		-

DEBT (Tables)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Debt

Our debt at June 30, 2015 is summarized below (in thousands):

Debt	Current		Long-term		Total
Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
Principal payments		(573)		-		(573)
Classification		1,234		(1,234)		-
Balance at Jun 30, 2015	$	2,419	$	7,008	$	9,427

Debt Discount	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(281)	$	(281)
Modification of warrants		-		(33)		(33)
Amortization expense		-		63		63
Balance at Jun 30, 2015	$	-	$	(251)	$	(251)

Debt Issuance Costs	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(162)	$	(162)
Additions		-		-		-
Amortization expense		-		34		34
Balance at Jun 30, 2015	$	-	$	(128)	$	(128)

Net Debt at Jun 30, 2015	$	2,419	$	6,629	$	9,048

Schedule of Interest Expense

Our interest expense during the three and six months ended June 30, 2015 and 2014 consisted of the following (in thousands):

	Three months Ended June 30,				Six months Ended June 30,
	2015		2014		2015		2014
Interest expense:
Term loan	$	251	$	255	$	512	$	510
Debt discount		33		30		63		59
Debt issue costs		17		17		34		34
Total interest expense	$	301	$	302	$	609	$	603

Schedule Of Long Term Debt Future Principal Payments Year

The remaining annual principal payments on the debt as of June 30, 2015 is as follows (in thousands):

Principal Payments
2015	$	1,185
2016		2,522
2017		2,741
2018		2,979
Total	$	9,427

SHARE-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2015

Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Our share-based compensation expense recognized in the Company’s results of operations comprised the following (in thousands):

	Three months Ended June 30,				Six months Ended June 30,
	2015		2014		2015		2014
Research and development expense:
Stock options	$	39	$	56	$	78	$	113

General and administrative expense:
Stock options	$	88	$	141	$	186	$	282
Restricted stock units		24		60		47		60
Subtotal	$	112	$	201	$	233	$	342

Total	$	151	$	257	$	311	$	455

Schedule of Share-based Compensation, Stock Options, Activity

Our stock option award activity during the six months ended June 30, 2015 and 2014 is shown below:

	Six months Ended June 30,
	2015				2014
	Number of Options (000’s)		Weighted Average Exercise Price		Number of Options (000’s)		Weighted Average Exercise Price
Outstanding, beginning		4,556	$	4.14		3,738	$	4.99
Granted		-		-		-		-
Exercised		-		-		(31)		1.30
Forfeited or expired		(75)		5.25		-		-
Outstanding, ending		4,481	$	4.13		3,707	$	5.02
Options exercisable		3,719	$	4.82		3,295	$	5.42

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans consisted of the following (in thousands):

	Six months Ended June 30,
		2015		2014
		Number of RSUs	Number of Vested RSUs	Number of RSUs	Number of Vested RSUs
Outstanding, beginning		147	147	829	829
Granted		206	-	147	-
Distributed		(129)	(129)	(829)	(829)
Vested		-	103	-	74
Forfeited or expired		-	-	-	-
Outstanding, ending		224	121	147	74

EARNINGS PER SHARE ("EPS") (Tables)

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Three months Ended June 30,				Six months Ended June 30,
	2015		2014		2015		2014
EPS – basic and diluted
Numerator: net loss	$	(2,663)	$	(3,521)	$	(1,424)	$	(7,609)
Denominator:
Common shares		49,163		48,848		49,055		48,846
Vested RSUs		70		-		46		-
Basic and diluted weighted average shares outstanding		49,233		48,848		49,101		48,846
EPS – basic and diluted	$	(0.05)	$	(0.07)	$	(0.03)	$	(0.16)

Excluded securities:
Common shares issuable:
Stock options		4,481		3,707		4,481		3,707
Nonvested RSUs		103		73		103		73
Common stock warrants		298		2,154		298		2,154
Total excluded common shares		4,882		5,934		4,882		5,934

License, Development, and Commercialization Agreements - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
	Mar. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Sep. 24, 2012
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description		Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Egalet also may terminate the Agreement prior to the launch of Oxaydo on 30 days prior written notice upon the occurrence of serious safety issues, regulatory restrictions and intellectual property issues, in each case involving Oxaydo
Inventory, Raw Materials and Supplies, Gross		$ 126,000	$ 260,000	$ 260,000
Percentage Of Inventory Allowance Reserve	100.00%
Licenses Revenue		250,000
Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Patents expiration year		expire between November 2023 and March 2025
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Percentage of royalty		5.00%
Payment for Termination		$ 2,000,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Line of Credit Facility, Description		Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and will pay us a $2.5 million milestone on the earlier to occur of (A) the launch of Oxaydo and (B) January 1, 2016
Minimum Net Sales Reaching Description		one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year
Minimum \| Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty		10.00%
Maximum \| Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty		15.00%

Revenue Recognition - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended			6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Sales Inducements, Additions				$ 255
Deferred Revenue, Revenue Recognized		314		314
Sales Returns Liability	195			195
Royalty revenue	0		1	0	4
Allowance for Sales Returns [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales Returns and Allowances, Goods				120
Pfizer [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty revenue					$ 4

Summary of Investments in Marketable Securities (Detail) (USD $) In Millions, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Marketable securities:
Corporate bonds - maturing within 1 year	$ 3.0	$ 3.5
Corporate bonds - maturing after 1 year and through March 2017	1.7	2.8
Total marketable securities	9.7	11.3
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 5.0	$ 5.0

Available for Sale Securities Continuous Unrealized Loss Position Fair Value (Detail) (USD $) In Millions, unless otherwise specified	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	$ 9.7	$ 11.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	9.7	11.3
Corporate Bonds
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	4.7	6.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	4.7	6.3
Exchange-traded funds
Available For Sale Securities Continuous Unrealized Loss Position Fair Value [Line Items]
Cost	5.0	5.0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 5.0	$ 5.0

Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) (USD $) In Millions, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Assets:
Total marketable securities	$ 9.7	$ 11.3
Corporate bonds
Assets:
Total marketable securities	4.7	6.3
Exchange-traded funds
Assets:
Total marketable securities	5.0	5.0
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	5.0	5.0
Fair Value, Inputs, Level 1 \| Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 1 \| Exchange-traded funds
Assets:
Total marketable securities	5.0	5.0
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	4.7	6.3
Fair Value, Inputs, Level 2 \| Corporate bonds
Assets:
Total marketable securities	4.7	6.3
Fair Value, Inputs, Level 2 \| Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 \| Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 \| Exchange-traded funds
Assets:
Total marketable securities	$ 0	$ 0

Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 24, 2012
Inventory [Line Items]
Raw and packaging materials	$ 126		$ 260			$ 260
Finished goods	264		44
Total	390		304
Less: reserve for raw materials	(126)	(260)	0
Less: reserve for finished goods	(47)		0	(68)	(133)
Net	$ 217		$ 304

Inventories - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 24, 2012
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross		$ 126	$ 260			$ 260
Inventory Reserve For Raw Materials	260	126	0
Cost of Goods Sold	255		220
Deferred Revenue, Current		0	353
Deferred Revenue, Revenue Recognized	314	314
Inventory Reserve For Finished Goods		$ 47	$ 0	$ 68	$ 133

Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Line Items]
Payroll, payroll taxes, and benefits	$ 165	$ 94
Professional services	436	253
Franchise taxes	19	13
Property taxes	15	15
Marketing and promotion	150	61
Clinical, non-clinical and regulatory services	24	83
Other fees and services	54	49
Total	$ 863	$ 568

Debt - Additional Information (Detail) (USD $) Share data in Thousands, except Per Share data, unless otherwise specified	0 Months Ended	6 Months Ended						1 Months Ended	6 Months Ended			6 Months Ended
	Jan. 07, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 27, 2013	Jun. 30, 2015 Maximum [Member]	Jun. 30, 2015 Minimum [Member]	Jul. 30, 2015 Subsequent Event [Member]	Jun. 30, 2015 Warrant	Jun. 30, 2015 After December 27 2015	Jun. 30, 2015 First Revenue Event Occurs	Jun. 30, 2015 Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument principal amount					$ 10,000,000
Debt instrument, interest rate, stated percentage		8.35%
Debt default long term debt percentage		13.35%
Debt Instrument, Maturity Date		Dec. 01, 2018
Debt instrument prepayment percentage										1.00%		2.00%
Debt instrument periodic payment terms balloon payment to be paid											795,000
Debt instrument, fee amount		50,000
Debt consulting placement fee		100,000
Debt related commitment fees and debt issuance costs		231,000
Debt instrument unamortized discount		251,000		281,000					400,000
Warrants to purchase common stock		298							298
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.504				$ 1.595	$ 0.504		$ 1.595
Warrants, expiry date									December 27, 2020
Debt instrument Cash Maintenance	2,500,000
Repayments of Debt	5,000,000	573,000	0
Additions To Debt Instrument Unamortized Discount		33,000
Debt Instrument, Periodic Payment		260,000
Debt instrument, periodic payment, principal		$ 573,000						$ 768,000
Debt Instrument, Interest Rate, Effective Percentage		10.16%

Summary of Debt (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015
Debt
Beginning of period	$ 10,000
Principal payments	(573)
Classification	0
End of period	9,427
Debt Discount
Beginning of period	281
Modification of warrants	33
Amortization expense	63
End of period	251
Debt Issuance Costs
Beginning of period	(162)
Additions	0
Amortization expense	34
End of period	(128)
Net Debt	9,048
Long-term Debt [Member]
Debt
Beginning of period	8,242
Principal payments	0
Classification	(1,234)
End of period	7,008
Debt Discount
Beginning of period	(281)
Modification of warrants	(33)
Amortization expense	63
End of period	(251)
Debt Issuance Costs
Beginning of period	(162)
Additions	0
Amortization expense	34
End of period	(128)
Net Debt	6,629
Short-term Debt [Member]
Debt
Beginning of period	1,758
Principal payments	(573)
Classification	1,234
End of period	2,419
Debt Discount
Beginning of period	0
Modification of warrants	0
Amortization expense	0
End of period	0
Debt Issuance Costs
Beginning of period	0
Additions	0
Amortization expense	0
End of period	0
Net Debt	$ 2,419

Interest Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Interest expense:
Term loan	$ 251	$ 255	$ 512	$ 510
Debt discount	33	30	63	59
Debt issue costs	17	17	34	34
Total interest expense	$ 301	$ 302	$ 609	$ 603

Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
2015	$ 1,185
2016	2,522
2017	2,741
2018	2,979
Total	$ 9,427	$ 10,000

Equity Financing - Additional Information (Detail) (USD $) Share data in Thousands, except Per Share data, unless otherwise specified	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 18, 2013	Jun. 30, 2015	Jun. 30, 2015 Common Stock [Member]	Jun. 30, 2015 Common Stock [Member]	Jun. 30, 2015 Placement Agency Agreement [Member]	Jun. 30, 2015 Securities Purchase Agreement [Member]
Equity Financing [Line Items]
Proceeds from sale of common stock	$ 13,000,000		$ 230,000	$ 230,000
Sale leaseback transaction, transaction costs, financing activities		8,000
Sale leaseback transaction, net proceeds, financing activities		220,000
Stock issued during period, shares, new issues			270	270	9,790	9,790
Share price					$ 0.01	$ 0.78
Proceeds from issuance of private placement					7,000,000	7,630,000
Description for repayment of placement agent					paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering
Placement agency reimbursed for expenses					$ 35,000

Common Stock Warrant Activity (Detail) (USD $)	6 Months Ended
Common Stock Warrant Activity (Detail) (USD $)	Jun. 30, 2015	Jun. 30, 2014
Number of Shares
Exercised	0
Warrant
Number of Shares
Number of Options Outstanding, beginning	298,000	2,154,000
Issued	0	0
Exercised	0	0
Expired	0	0
Number of Options Outstanding, ending	298,000	2,154,000
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 1.60	$ 3.15
Issued	$ 0	$ 0
Exercised	$ 0	$ 0
Expired	$ 0	$ 0
Weighted Average Exercise Price, ending	$ 0.50	$ 3.15

Common Stock Warrants - Additional Information (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2015
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	298
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.504
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	298
Common stock Warrant expiration date	December 27, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.595

Share-Based Compensation - Additional Information (Detail) (USD $)	6 Months Ended			1 Months Ended	6 Months Ended			0 Months Ended	1 Months Ended		2 Months Ended	12 Months Ended	8 Months Ended			0 Months Ended
	Jun. 30, 2015	Jun. 30, 2015 Stock options	Jun. 30, 2015 Option Plan [Member]	Jan. 31, 2014 2005 Restricted Stock Unit Award Plan [Member]	Jun. 30, 2015 2005 Restricted Stock Unit Award Plan [Member]	Jun. 30, 2015 2014 Restricted Stock Unit Award Plan [Member]	May 01, 2014 2014 Restricted Stock Unit Award Plan [Member]	May 01, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Dec. 31, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Sep. 30, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Jun. 30, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Dec. 31, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member] Settled In Cash [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member] Convertible Common Stock [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Subsequent Event [Member] Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Withholding tax obligations		$ 36,000
Restricted Stock Units Sale Price	$ 0.01
Shares withheld upon elections made to exchange RSUs		18,000		330,000
Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations				500,000
Number of vested shares distributed to holders				500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								37,000								51,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage									25.00%	25.00%	50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description								stock, for up to 40%								stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value												26,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					one-fourth of vested shares of common stock underlying RSU awards of 3.3 million shares will be distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	31,000	24,000										129,000	30,000	99,000
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution													18,000
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings			13,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award						1,650,000
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 49,000

Recognition of Share-Based Compensation Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and Development Expense, Total	$ 511	$ 1,281	$ 1,475	$ 2,719
General and administrative expense	112	201	233	342
Share Based Compensation Expense Recognized In Operations	151	257	311	455
Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and Development Expense, Total	39	56	78	113
General and administrative expense	88	141	186	282
Restricted Stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	$ 24	$ 60	$ 47	$ 60

Stock Option Award Activity (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Exercised	0
Stock Option Plan
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	4,556	3,738
Number of Options, Granted	0	0
Number of Options, Exercised	0	(31)
Number of Options, Forfeited or expired	(75)	0
Number of Options Outstanding, ending	4,481	3,707
Number of Options exercisable	3,719	3,295
Weighted Average Exercise Price, beginning	$ 4.14	$ 4.99
Weighted Average Exercise Price, Granted	$ 0	$ 0
Weighted Average Exercise Price, Exercised	$ 0	$ 1.3
Weighted Average Exercise Price, Forfeited or expired	$ 5.25	$ 0
Weighted Average Exercise Price, ending	$ 4.13	$ 5.02
Weighted Average Exercise Price, Options exercisable	$ 4.82	$ 5.42

Summary of RSU Plan (Detail) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Restricted Stock Units
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	147	829
Granted	206	147
Distributed	(129)	(829)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	224	147
Vested Restricted Stock Units (RSUs)
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	147	829
Granted	0	0
Distributed	(129)	(829)
Vested	103	74
Forfeited or expired	0	0
Outstanding, ending	121	74

Income Taxes - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended	6 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2014	Jun. 30, 2015 Federal Research and Development	Dec. 31, 2014 Federal Research and Development	Jun. 30, 2015 Indiana State Research and Development	Dec. 31, 2014 Indiana State Research and Development	Dec. 31, 2014 Maximum	Dec. 31, 2014 Minimum
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 51.5
Federal NOLs	151.4
U.S. statutory tax rate	34.00%
NOL expiration year						2034	2016
Research and development tax credits			1.1		0.3
Research and development expiration period		which expire in the years 2024 through 2034		which expire in the years 2015 through 2017
State income tax benefits	$ 2.9

Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
EPS - basic and diluted
Numerator: net loss	$ (2,663)	$ (3,521)	$ (1,424)	$ (7,609)
Denominator:
Common shares	49,163	48,848	49,055	48,846
Vested RSUs	70	0	46	0
Basic and diluted weighted average shares outstanding	49,233	48,848	49,101	48,846
EPS - basic and diluted	$ (0.05)	$ (0.07)	$ (0.03)	$ (0.16)
Common shares issuable:
Total excluded common shares	4,882	5,934	4,882	5,934
Stock options
Common shares issuable:
Total excluded common shares	4,481	3,707	4,481	3,707
Nonvested RSUs member
Common shares issuable:
Total excluded common shares	103	73	103	73
Common stock warrants
Common shares issuable:
Total excluded common shares	298	2,154	298	2,154

Commitments and Contingencies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	150
Number of lawsuits served	50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint	445
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space	$ 25
Lease expiring date	March 31, 2016

Accounting Pronouncements - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt Instrument Issuance Cost	$ 128	$ 162

Research and Development Activities - Additional Information (Detail) (USD $)	Jun. 30, 2015	Dec. 31, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued Research And Development Expense Current	$ 0	$ 0
Prepaid Research And Development Expense Current	$ 0	$ 0